Heartseed News

Heartseed: Notice Regarding the Revisions of Full-Year Financial Results Forecast for the Fiscal Year Ending October 31, 2024

Oct 16 03:00 ET

Heartseed: Notice regarding revisions to earnings forecasts for the fiscal year ending 2024/10

Oct 16 02:30 ET

Heartseed: Change report.

Oct 11 02:23 ET

Heartseed: Change Report

Oct 10 04:19 ET

Heartseed: Change report.

Oct 10 04:18 ET

Heartseed: Notice of completion of safety evaluation committee review on administration of HS-001 LAPIS test high dose group first case

Oct 1 02:30 ET

Heartseed: [Delayed] Financial Results for the Nine Months Ended July 31, 2024 (Under Japan GAAP)(Non-consolidated)

Sep 13 02:30 ET

Heartseed: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/10 [Japanese GAAP] (unconsolidated)

Sep 12 02:00 ET

Heartseed: Announcements of individual stock regarding the results of third-party allocation of capital increase.

Aug 23 02:40 ET

Heartseed: Mass Ownership Report

Aug 6 02:18 ET

Heartseed: Report on Corporate Governance, 02 August 2024.

Aug 2 00:56 ET

Heartseed: Mass Ownership Report

Aug 1 03:26 ET

Heartseed: Mass Ownership Report

Aug 1 03:23 ET

Heartseed: Report on a large shareholding

Aug 1 03:20 ET

Heartseed: Mass Ownership Report

Aug 1 03:16 ET

Heartseed: Independent Company Executives Declaration

Jul 29 19:45 ET

Heartseed: Articles of Incorporation 2024/04/17

Jul 29 19:31 ET

Heartseed: Corporate Governance Report: 07/30/2024

Jul 29 19:30 ET

Heartseed: Heartseed announced a positive recommendation from the safety monitoring committee regarding dose escalation in Phase 1/2 clinical trials administered with HS-001.

Jul 29 19:00 ET

Heartseed: In the HS-001 LAPiS trial, the Safety Evaluation Committee recommended the start of administration in the high-dose group.

Jul 29 19:00 ET